Table 2.
Characteristics of CPAP therapy interventions and outcomes.
| Study | CPAP Use, h/night | AHI, events/h | OSA Diagnosis | Outcomes | |
|---|---|---|---|---|---|
| CPAP | CO | ||||
| Capodanno et al20, 2014 | NR | >15 | >15 | PD | Death, MI, revascularization, stroke |
| Cassar et al26, 2007 | NR | ≥15 | ≥15 | PSG | Death, severe angina, MI, PCI, CABG |
| Huang et al15, 2015 | ≥4 | ≥15 | ≥15 | PD | Death, revascularization, MI, HF, SBP, DBP |
| Huang et al28, 2016 | 4.2 ± 1.1 | 28.5 ± 12.0 | 28.9 ± 12.2 | PD | TG, TC, LDL-C, HDL-C |
| Lee et al21, 2017 | ≥4 | 49.8 ± 31.3 | 49.8 ± 31.3 | PSG | Death, MI, revascularization, stroke |
| McEvoy et al13, 2016 | <4 | ≥15 | ≥15 | PD | Death, revascularization, MI, HF, UA, AF, SBP, DBP |
| Milleron et al22, 2004 | 5.7 ± 1.5 | 33.7 ± 16.8 | 29.0 ± 12.8 | PSG | Death, HF, PTCA, ACS |
| Nakashima et al23, 2015 | NR | >20 | >20 | PSG | Death, ACS, HF |
| Peker et al29, 2016 | ≥4 | ≥15 | ≥15 | PSG | Death, MI, revascularization |
| Peker et al14, 2020 | <4 | ≥15 | ≥15 | PSG | Death, MI, revascularization |
| Sánchez-de-la-Torre et al16, 2019 | <4 | ≥15 | ≥15 | PSG | Death, MI, HF, UA, AF |
| Wu et al27, 2015 | ≥4 | ≥15 | ≥15 | PSG/PD | Death, MI, revascularization, stent thrombosis |
| Yang et al24, 2013 | 5 ± 1 | 25 ± 13 | 30 ± 15 | PD | Glucose |
| Zhao et al25, 2012 | 5.1 ± 0.8 | 26.9 ± 11.9 | 28.1 ± 16.1 | PD | SBP, DBP |
ACS = acute coronary syndrome, AF = atrial fibrillation, AHI = apnea-hypopnea index, CABG = coronary artery bypass graft, CO = control, CPAP = continuous positive airway pressure, DBP = diastolic blood pressure, HDL-C = high-density-lipoprotein cholesterol, HF = heart failure, LDL-C = low-density-lipoprotein cholesterol, MI = myocardial infarction, NR = not reported, OSA, obstructive sleep apnea, PCI = percutaneous coronary intervention, PD = portable device, PSG = polysomnography, PTCA = percutaneous transluminal coronary angioplasty, SBP = systolic blood pressure, TC = total cholesterol, TG = triglycerides, UA = unstable angina.